![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 35, 24935-24940, August 27, 1999
From the Department of Pharmacology, Vanderbilt University Medical
Center, Nashville, Tennessee 37232-6600
Agonist-elicited receptor sequestration is
strikingly different for the The three subtypes of Recent reports suggest that internalization is required for some G
protein-coupled receptors (GPCRs) to stimulate the MAP kinase cascade
(4-6). The purpose of the current studies was to determine if the
differing profiles of agonist-induced internalization of the
Cell Culture
HEK 293 cells were maintained in DMEM containing 10% fetal calf
serum at 37 °C in a 5% CO2 incubator. Permanent
transfectants were generated by LipofectAMINE-mediated co-transfection
of the cells with plasmids containing the indicated receptors and a
neomycin resistance gene. Cells that survived selection in medium
containing 500 µg/ml G418 were screened for expression of the
expected receptor by binding of the radiolabeled MAP Kinase Stimulation
Permanent transfectants of HEK 293 cells were plated on 60-mm
dishes and allowed to multiply until they reached a density of
60-80%. The cells were then serum-deprived overnight. On the day of
the experiment, the medium was replaced with fresh serum-free DMEM,
DMEM supplemented with 250 µg/ml concanavalin A, or
K+-depleted medium as described below to block
clathrin-mediated endocytosis. After the pretreatment, the indicated
drugs were added directly to the medium on the cells and were swirled
to mix. After the indicated times, the cells were washed once with Dulbecco's phosphate-buffered saline containing 1 mM
MgCl2 and 0.5 mM CaCl2
(PBS/Ca2+/Mg2+) and then lysed in SDS sample buffer
(62.5 mM Tris-HCl, pH 6.8; 2% w/v SDS; 10% glycerol; 50 mM dithiothreitol) supplemented with 1 mM
sodium orthovanadate (Sigma), 10 units/ml leupeptin (Sigma), and 10 units/ml aprotinin (Bayer Corp., Kankakee, IL). The lysates were
transferred to an Eppendorf tube on ice. When all samples were
collected, they were bath sonicated for 30-40 s, then placed in a
heating block at 90 °C, allowed to warm to 95 °C, and incubated at 95 °C for 5 min. The lysates were then spun in a microcentrifuge at room temperature for 5 min to remove debris. The supernatants were
assayed in Bio-Rad's protein assay for relative protein concentration, and equivalent amounts of protein were loaded on a 10%
SDS-polyacrylamide gel for electrophoresis. The gel was run for 160 mA-h and then transferred overnight onto nitrocellulose in transfer
buffer (20% methanol; 0.19 M glycine; 25 mM
Tris base) at 33 mV.
MAP kinase activation was evaluated using an antibody that recognizes
dually phosphorylated (Thr/Tyr) MAP kinase (Promega catalog number
V6671) and normalized to total MAP kinase using an antibody that
recognizes MAP kinase regardless of its phosphorylation state (New
England Biolabs catalog number 9102). To assess activated MAP kinase
content, the nitrocellulose blot was incubated in blocking buffer (1×
TBS; 0.1% Tween 20; 5% w/v nonfat dry milk) for 1 h at room
temperature and then probed with rabbit polyclonal antibody (from
Promega) to dually phosphorylated MAP kinase, diluted 1/500 in blocking
buffer, for 1 h at room temperature. The blot was washed three
times for 5 min each with TBST (2.42 g/liter Tris base; 8.0 g/liter
sodium chloride; 0.1% Tween 20; pH 7.6) and then probed with donkey
anti-rabbit horseradish peroxidase-linked secondary antibody (1/2000
dilution in blocking buffer) (Amersham Pharmacia Biotech) for 1 h
at room temperature. The wash protocol was repeated, and the
immunoreactive bands were detected by enhanced chemiluminescence
(Amersham Pharmacia Biotech). The blots were then stripped with
stripping buffer (62.5 mM Tris-HCl, pH 6.8; 2% SDS; 100 mM 2-mercaptoethanol) for 30 min at 65 °C and reprobed with antibody to total MAP kinase (New England Biolabs) at a 1/500 dilution in blocking buffer overnight at 4 °C, followed by donkey anti-rabbit secondary antibody as described above.
To semi-quantify MAP kinase activation, the enhanced chemiluminescence
(ECL) images were scanned into Adobe Photoshop with a UMAX Astra 600 scanner, and the band intensities were measured using NIH Image
software. Background pixel density was subtracted from each band's
pixel density. The corrected pixel density for active MAP kinase was
divided by the corrected pixel density for total MAP kinase to obtain
the normalized levels of activated MAP kinase reported in the figures
as "active/total."
Cell Surface Receptor Quantitation via Intact Cell ELISA
The introduction of the HA epitope into the amino terminus of
Reversible Biotinylation Strategy to Quantify Receptor
Internalization
Surface receptors were biotinylated on ice with
disulfide-cleavable biotin (sulfo-NHS-SS-biotin; Pierce) and treated
with a hydrophilic reducing agent, mercaptoethanesulfonic acid (MESNA), after termination of the surface biotinylation reaction. Receptors that
are inside the cell at the time of MESNA treatment are protected from
reduction and therefore subsequently isolated from the detergent extract by adsorption to streptavidin-agarose. Our protocol was adapted
from a previously published procedure (8). For each experiment, HEK 293 clonal cell lines were plated on 60-mm dishes coated with
poly-D-lysine and allowed to grow to 70-80% confluence. Cells were serum-starved for 16-18 h prior to each experiment. On the
day of the experiment, cells were first treated with serum-free DMEM
with or without 250 µg/ml concanavalin A or with
K+-depleted medium as described below. Subsequent steps
were performed at 4 °C as follows: cells were washed twice with
ice-cold phosphate-buffered saline (PBS) containing 1 mM
MgCl2 and 0.5 mM CaCl2 or with
K+ depletion buffer and then incubated with 100 µg/ml
sulfo-NHS-SS-biotin in PBS/Ca2+/Mg2+ or
K+ depletion buffer for 30 min at 4 °C. The cells were
washed twice with PBS/Ca2+/Mg2+ and once with
serum-free DMEM or with K+ depletion buffer at 4 °C.
Dishes were then incubated at 37 °C by placement on a rack in a
water bath. For agonist activation, the medium was replaced with
37 °C serum-free DMEM or K+ depletion buffer containing
100 µM epinephrine for 5 min at 37 °C (control cells
had their medium replaced with warm medium without agonist). The
incubation was terminated by replacement of the 37 °C medium with
ice-cold DMEM or K+ depletion buffer. The culture dishes
were returned to 4 °C, washed twice with ice-cold
PBS/Ca2+/Mg2+, and then incubated with 250 mM MESNA in PBS/Ca2+/Mg2+ for two
20-min incubations to release surface-accessible biotinylating reagent
via disulfide exchange. The cells were then washed twice with ice-cold
serum-free DMEM, and the reducing effect of any residual MESNA was then
quenched by incubation with 5 mg/ml iodoacetamide in
PBS/Ca2+/Mg2+ for 20 min at 4 °C.
Biotinylated receptors resistant to MESNA reversal of biotinylation
were defined as "inaccessible." To define total MESNA-accessible
receptors on these cell lines, one 60-mm dish per experiment was
treated with MESNA immediately following biotinylation at 4 °C to
reveal the quantity of surface receptor biotinylation that MESNA can
reverse efficiently.
To isolate biotinylated Treatments for Blocking Receptor Internalization
Potassium Depletion--
The potassium depletion protocol for
blocking receptor endocytosis was adapted from previously published
methods (9, 10). Clonal cell Lines expressing either
Concanavalin A Pretreatment--
Clonal cell lines expressing
either Hypertonic Sucrose Treatment--
Clonal cell lines expressing
either Co-expression of K44A Dominant Negative Dynamin--
Parental
HEK 293 cells were plated on 6-well plates or 35-mm culture dishes and
transiently transfected with cDNAs encoding the HA-tagged
Receptor internalization also can be examined by quantifying the
fraction of surface receptors that moves in a
time-dependent fashion to an inaccessible compartment. For
these studies, we exploited a reversible biotinylating agent,
sulfo-NHS-SS-biotin (Fig. 1B). Biotin remaining on the
surface at the end of a particular treatment protocol was removed by
treatment with MESNA, a non-permeant reducing agent that cleaves the
disulfide bond and liberates the biotinylating reagent from proteins
still accessible at the cell surface. MESNA reversal immediately after
biotinylation (Fig. 1B; time 0, +) provides an assessment of
the amount of biotinylated receptor that is accessible to this reversal
reagent at time 0. Further incubation of the cells at 37 °C in the
absence or presence of agonist before MESNA reversal of surface
biotinylation permits evaluation of agonist-independent
versus agonist-accelerated receptor redistribution. As shown
in Fig. 1B, the Blockade of
To assess directly the impact of internalization on MAP kinase
activation, we utilized four independent experimental manipulations previously demonstrated to block internalization by clathrin-coated pit
pathways as follows: hypertonic sucrose (9), pretreatment with
concanavalin A (11), exposure to K+ -depleted medium (9),
and co-expression with dominant negative (K44A) dynamin (18, 19).
Hypertonic sucrose proved a non-viable strategy in our HEK 293 cell
lines, as it caused MAP kinase activation to occur without agonist
addition and to a similar extent in parental HEK 293 cells as in
permanent transfectants expressing
A third experimental manipulation, co-expression of dominant negative
dynamin (K44A), was explored as a tool to block agonist-elicited internalization. However, as assessed in the reversible biotinylation assay, overexpression of dynamin K44A (assessed by Western blotting) did not eliminate
A fourth experimental manipulation that blocks receptor internalization
via clathrin-coated pits, pretreatment in K+-depleted
medium, was successful in probing the relationship between receptor
internalization and MAP kinase activation. As shown in Fig.
4A, exposure to
K+-depleted medium blocks biotinylated surface
The present studies provide two lines of evidence that
The reason for the discrepancy between our findings and those
previously reported for other G protein-coupled receptors is not
certain. The simplest interpretation is that different GPCRs have
different mechanistic requirements to stimulate MAP kinase. However, it
is also important to note that interpretations from previous studies
relied at least in part on transient expression of receptors (4) or on
transient expression of dominant negative structures of dynamin or
arrestin to block internalization of heterologous or endogenous
receptors (4). Our findings suggest that agonist-elicited
redistribution of the Our findings provide strong evidence that G protein-coupled receptor
internalization is not a general prerequisite for activation of the MAP
kinase cascade via Gi-coupled receptors (Fig. 4). Similar results have been obtained previously with chemokine receptors (24).
Our results also suggest that MAP kinase activation may be terminated
by internalization, since activation of MAP kinase by the
We thank Carol Ann Bonner for the
establishment and maintenance of stably transfected HEK 293 cell lines
and all members of the Limbird laboratory for helpful scientific discussions.
*
This work was supported in part by National Institutes of
Health Grant HL 25182.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Dept. of Pharmacology,
Vanderbilt University Medical Center, Nashville, TN 37232-6600. Tel.:
615-343-3538; Fax: 615-343-1084; E-mail: Lee.Limbird@mcmail. vanderbilt.edu.
The abbreviations used are:
AR, adrenergic
receptor;
MAP kinase, mitogen-activated protein kinase;
ELISA, enzyme-linked immunosorbent assay;
MESNA, mercaptoethanesulfonic acid;
HEK, human embryonic kidney;
GPCR, G protein-coupled receptor;
DMEM, Dulbecco's modified Eagle's medium;
PBS, phosphate-buffered saline;
HA, hemagglutinin.
Stimulation of Mitogen-activated Protein Kinase by G
Protein-coupled
2-Adrenergic Receptors Does Not
Require Agonist-elicited Endocytosis*
and
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2A-
versus
2B-adrenergic receptor
(
2-AR) subtypes; the
2B-AR undergoes
rapid and extensive disappearance from the HEK 293 cell surface,
whereas the
2A-AR does not (Daunt, D. A., Hurt, C.,
Hein, L., Kallio, J., Feng, F., and Kobilka, B. K. (1997) Mol. Pharmacol. 51, 711-720; Eason, M. G., and
Liggett, S. B. (1992) J. Biol. Chem. 267, 25473-25479). Since recent reports suggest that endocytosis is
required for some G protein-coupled receptors to stimulate the
mitogen-activated protein (MAP) kinase cascade (Daaka, Y., Luttrell,
L. M., Ahn, S., Della Rocca, G. J., Ferguson, S. S.,
Caron, M. G., and Lefkowitz, R. J. (1998) J. Biol.
Chem. 273, 685-688; Luttrell, L. M., Daaka, Y., Della Rocca, G. J., and Lefkowitz, R. J. (1997) J. Biol.
Chem. 272, 31648-31656; Ignatova, E. G., Belcheva, M. M., Bohn, L. M., Neuman, M. C., and Coscia, C. J. (1999)
J. Neurosci. 19, 56-63), we evaluated the
differential ability of these two subtypes to activate MAP kinase. We
observed no correlation between subtype-dependent
agonist-elicited receptor redistribution and receptor activation of the
MAP kinase cascade. Furthermore, incubation of cells with
K+-depleted medium eliminated
2B-AR
internalization but did not eliminate MAP kinase activation, suggesting
that receptor internalization is not a general prerequisite for
activation of the MAP kinase cascade via Gi-coupled
receptors. We also noted that neither dominant negative dynamin (K44A)
nor concanavalin A treatment dramatically altered MAP kinase activation
or receptor redistribution, indicating that these experimental tools do
not universally block G protein-coupled receptor internalization.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2-adrenergic receptors
(
2-AR)1 signal
via the Gi/Go subfamily of G proteins to effect
several downstream signaling events (1). Since all three receptor
subtypes appear to couple to the same effectors, it is of interest to
explore other differences among these subtypes in an effort to
understand the functional relevance of subtype diversity. Two
2-AR subtypes manifest differences in agonist-induced
receptor redistribution from the cell surface as follows: the
2B-AR becomes rapidly and extensively internalized
following agonist occupancy, whereas the
2A-AR does not
readily redistribute to an intracellular compartment following agonist
occupancy (2, 3). The
2C-AR exists both on the surface
and in an intracellular compartment at steady state (2), confounding
quantitative assessment of
2C-AR redistribution.
2A-AR and
2B-AR subtypes are paralleled
by differing rates or extents of MAP kinase activation and whether
agents that interfere with agonist-elicited receptor redistribution
alter MAP kinase activation.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2-AR
antagonist, [3H]rauwolscine. Clonal cell lines with
varying levels of
2-AR expression were kept for further
study. The experiments reported here were performed on an
2A-AR expressing cell line that contains 7-8 pmol of
receptor per mg of protein and an
2B-AR-expressing cell
line that contains 2-4 pmol/mg.
2-ARs expressed in HEK 293 cells provided a tool for
quantitation of receptors expressed at the cell surface using a cell
surface ELISA, as described previously (2, 7). On day 1, HEK 293 cells
stably expressing the receptors of interest were plated on
poly-D-lysine-coated 96-well culture plates at a density of 20,000 cells/well. On day 2, the cells were serum-starved overnight. On
the morning of day 3, the cells were treated in the absence or presence
of agonist as indicated in the figure legends and then washed twice in
PBS/Ca2+/Mg2+ to stop the drug treatment and
fixed in 4% paraformaldehyde containing 0.12 M sucrose for
20 min at room temperature. The wells were washed three times with
PBS/Ca2+/Mg2+ and then incubated for 30 min at
37 °C in DMEM containing 10% sheep serum to block nonspecific
antibody binding in subsequent incubations. The 12CA5 antibody directed
against the HA epitope was diluted 1/100 in blocking medium and applied
for 1 h at 37 °C. The cells were then washed 3 times for 5 min
each in PBS/Ca2+/Mg2+ at room temperature. The
sheep anti-mouse secondary antibody (Amersham Pharmacia Biotech) was
applied at a 1/2500 dilution in blocking medium for 1 h at
37 °C. The wells were then washed three times for 5 min at room
temperature in PBS/Ca2+/Mg2+, as above. The
colorimetric substrate o-phenylenediamine dihydrochloride (1 mg/ml, Pierce) was added and incubated for 20 min to 1 h at 15 °C. The color development was stopped by the addition of an equal
volume of 1 M sulfuric acid. The absorbance at 490 nm in each well was read on a microtiter plate reader. Generally, four replicates of each treatment were performed per experiment.
2-AR, cells were lysed in
solubilization buffer (4 mg/ml dodecyl-
-D-maltoside
(Calbiochem), 0.8 mg/ml cholesteryl hemisuccinate (Sigma), 1 mg/ml
iodoacetamide (Sigma), 20% glycerol, 25 mM glycyl glycine,
5 mM EDTA, 20 mM HEPES, pH 8.0, 0.1 M NaCl) and homogenized by 5 up/down passages through a
25-gauge needle. Cellular debris was removed by centrifugation in a
microcentrifuge at 4 °C for 1 h. The supernatant (defined as
the detergent-solubilized extract) was incubated with
streptavidin-agarose (80 µl, 1:1 slurry) for 1 h at room
temperature. The pass-through was saved, and the beads were washed 3 times with a 1:8 dilution of the solubilization buffer in "binding
buffer" (25 mM glycyl glycine; 5 mM EDTA; 20 mM HEPES, pH 8.0; 0.1 M NaCl). Proteins were
eluted from streptavidin-agarose in Laemmli buffer containing 15 µg/ml dithiothreitol. The entire eluate was separated by
SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose,
and probed with a 1:1000 dilution in blocking buffer (see above) of
HA.11 antibody from Babco to the HA-tagged
2-ARs.
Horseradish peroxidase-conjugated sheep anti-mouse secondary antibody
(Amersham Pharmacia Biotech) was used at a 1/3000 dilution in blocking
buffer. Reactive proteins were visualized by ECL (Amersham Pharmacia
Biotech). Bands were quantified by scanning and NIH Image software as
described above. To calculate percent internalization, the intensity of
the band in the lane where cells were immediately exposed to MESNA
(labeled 0', 4 °C) is subtracted as background from all other band
intensities, and then the band intensity in the treated lanes ("no
epinephrine" or "+epinephrine" after 5 min at 37 °C) is
divided by the "total" band intensity, and the result is multiplied
by 100.
2-AR subtype were incubated at 37 °C for 5 min in
hypotonic shock solution (serum-free DMEM and distilled water in a 1:1
ratio). Then they were rinsed once in K+ depletion buffer
(100 mM NaCl; 50 mM HEPES, pH 7.4; 1 mM CaCl2; 1 mM MgCl2)
and then incubated in the same buffer for 1 h at 37 °C.
(Control cells were treated with PBS instead of potassium depletion
buffer.) MAP kinase stimulation or biotinylation then proceeded as
described above.
2-AR subtype were incubated with 250 µg/ml
concanavalin A (Sigma), made fresh daily in serum-free DMEM, for 30 min
at 37 °C, as described previously (11). MAP kinase stimulation or
biotinylation then proceeded as described above.
2-AR subtype were washed once and then incubated
for 1 h at 37 °C with DMEM containing 0.45 M
sucrose, as described previously (9). Drug treatment and analysis then
proceeded as described.
2B-AR and either dominant negative dynamin cDNA (kindly provided by Mark Caron) or "empty" pCMV4 vector as a
control. FuGENE 6 transfection reagent (Roche Molecular Biochemicals)
was used according to package directions with a FuGENE
6/
2B-AR plasmid/dynamin K44A or control plasmid ratio of
6 µl/1 µg/2 µg. Internalization and MAP kinase activation were
assayed as described above. Two wells of a 6-well plate were combined
for each data point.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2-AR Subtypes Possess Differing Profiles of
Agonist-induced Receptor Redistribution--
Two independent
experimental strategies were used to examine agonist-elicited receptor
redistribution of
2-AR subtypes. An intact cell ELISA
performed on HEK 293 cells stably expressing HA-tagged mouse
2A-AR and
2B-AR (see "Experimental
Procedures") was used to assess loss of receptor from the cell
surface (Fig. 1A). Cell
surface ELISAs corroborate earlier morphological findings (2, 3) that
the
2A-AR and
2B-AR show differing
profiles of agonist-induced internalization. Whereas the
2A-AR demonstrates negligible loss of surface receptors
following exposure to maximal agonist concentrations, the
2B-AR subtype demonstrates a 30-40% loss of
surface-accessible epitope over the same time.

View larger version (27K):
[in a new window]
Fig. 1.
The
2B-AR subtype, but not the
2A-AR subtype, rapidly leaves the
surface for an inaccessible compartment following agonist
occupancy. A, clonal HEK 293 cell lines expressing
2A-AR (closed symbols) or
2B-AR (open symbols) were stimulated with 100 µM epinephrine for the indicated times. Endocytosis was
monitored by an intact cell ELISA (see "Experimental Procedures").
The values shown are means ± S.D. for n = 3 or
more individual experiments for all time points except for the
2A-AR at 60 min, for which n = 1. B, reversible biotinylation also demonstrates differing
profiles of internalization. The 1st lane
represents total receptor biotinylated on the cell surface at the end
of the incubation with sulfo-NHS-SS-biotin (see "Experimental
Procedures"). The 2nd lane demonstrates the
effectiveness of MESNA, a membrane-impermeant reducing agent, in
reversing the surface biotinylation just after it occurs. Biotinylated
cells were then incubated for 5 min at 37 °C without (3rd lane) or with (4th lane) epinephrine
as agonist. ECL images are representative of three Western blots.
Biotinylated receptors were quantified using NIH image, and the
percentage internalized in three separate experiments are shown in the
lower panel as the mean ± S.E. Values were compared
using two-tailed t tests: *, p = 0.007, #,
p = 0.0005.
2A-AR is not extensively redistributed to a MESNA-inaccessible compartment at 37 °C, even in
the presence of the agonist epinephrine, whereas the
2B-AR is rapidly internalized (i.e. removed
from MESNA accessibility), and this internalization is enhanced by
agonist stimulation.
2A-AR and
2B-AR Subtypes Evoke
Similar Profiles of MAP Kinase Stimulation--
Previous studies in
heterologous systems have demonstrated
2-AR-elicited
activation of MAP kinase (12-16). Recent findings suggest that G
protein-coupled receptors may require internalization to activate MAP
kinase, particularly via pertussis toxin-sensitive pathways (4, 5). To
assess whether receptor internalization is required for MAP kinase
activation by
2-ARs, we exploited the differential
internalization profiles of the
2A-AR and
2B-AR subtypes and compared their ability to activate
MAP kinase in permanent transfectants of HEK 293 cell lines. As shown
in Fig. 2, the extent of MAP kinase
activation by these two receptor subtypes is similar when measured by
the appearance of dually phosphorylated Erk 1 and Erk 2. Stimulation by
both subtypes was sensitive to pertussis toxin pretreatment (data not
shown), indicating that
2A-AR and
2B-AR
are activating MAP kinase via a Gi-coupled pathway, as
observed previously (17). We are confident that the stimulation of MAP
kinase by epinephrine demonstrated in Fig. 2 is due to activation of
the heterologously expressed
2A-AR or
2B-AR in the HEK 293 cells, as activation of MAP kinase
is also elicited by the
2-AR agonist UK 14,304 and is
blocked by the
2-AR-specific antagonists yohimbine and
RX 821002 (data not shown). Furthermore, parental HEK 293 cells did not
demonstrate activation by epinephrine prior to introduction of the
2-AR-encoding cDNAs. Unlike the properties of some
clonal HEK 293 cell lines reported in the literature (4), we have found
no evidence for
-AR stimulation of MAP kinase in our HEK 293 cells,
as MAP kinase is not activated by isoproterenol and the response to
epinephrine was not blocked by the
-AR antagonist, propranolol.

View larger version (16K):
[in a new window]
Fig. 2.
Similar levels of MAP kinase activation
by
2A-AR and
2B-AR subtypes. Clonal HEK 293 cell lines expressing the
2A-AR (A) or
2B-AR (B) were treated for the indicated
times with 100 µM epinephrine. MAP kinase activity was
assessed by Western blotting for dually phosphorylated MAP kinase and
normalized by Western blotting for total MAP kinase. Upper
panels, ECL images of Western blots for dually phosphorylated
(active) MAP kinase. Images are representative of at least four
experiments. Lower panels, normalized levels of activated
MAP kinase, expressed as the ratio of active to total MAP kinase enzyme
(mean ± S.E. for four experiments). (See "Experimental
Procedures.")
2B-AR Internalization Does Not Block MAP
Kinase Activation--
The observation that both
2A-AR
and
2B-AR subtypes stimulate MAP kinase suggests that
receptor internalization, which is highly efficient for the
2B-AR but not for
2A-AR subtype, is not
required for MAP kinase activation. Consistent with this interpretation is the realization that maximal MAP kinase activation occurs at 2 min,
a time when agonist-elicited receptor loss from the surface, even for
2B-AR, is just beginning (see Fig.
1A).
2-AR subtypes. A
second treatment, concanavalin A, is thought to prevent internalization of GPCRs by stabilizing surface integrity due to tetravalent lectin contacts (11). However, concanavalin A was only variably successful in
blocking
2B-AR internalization, when assessed via the
redistribution of biotinylated
2B-AR into a
MESNA-inaccessible compartment (data not shown). This lack of
consistent inhibition of
2B-AR internalization may be a
consequence of the non-glycosylated nature of the
2B-AR subtype (20). Nevertheless, this finding confounds the use of concanavalin A as a tool for assessing the role of internalization of
this subtype in stimulation of MAP kinase.
2B-AR internalization, suggesting that
these receptors can be internalized via a dynamin-independent pathway (Fig. 3A). Dynamin-independent
endocytosis of G protein-coupled receptors has also been noted for
dopaminergic and M2 muscarinic receptor subtypes (21, 22). Not
surprisingly, co-expression of dynamin K44A with the
2B-AR did not markedly alter MAP kinase activation by
the
2B-AR (Fig. 3B).

View larger version (69K):
[in a new window]
Fig. 3.
Dynamin K44A does not block endocytosis
of
2B-AR or
2B-AR activation of MAP kinase.
The
2B-AR was transiently expressed in HEK 293 cells
with or without dominant negative dynamin (K44A) as described under
"Experimental Procedures." A, receptor redistribution to
a MESNA-inaccessible compartment was evaluated as in Fig. 1B
(see "Experimental Procedures") and quantified for three
independent experiments (mean ± S.E.). In these experiments,
internalization was assessed at the 20-min time point, because
internalization was undetectable at the 5-min time point in transiently
transfected cells. B, MAP kinase activation by epinephrine
was evaluated in the absence (upper panel) or presence
(middle panel) of dynamin K44A and was quantified for four
independent experiments (mean ± S.E.), as shown in the
bottom panel.
2B-AR redistribution into a MESNA-inaccessible
compartment, consistent with blockade of
2B-AR
internalization. However, as shown in Fig. 4B,
2B-AR readily activates MAP kinase in response to
epinephrine under the same conditions. These results demonstrate that
internalization is not required for the
2B-AR to
stimulate MAP kinase. In fact, the duration of MAP kinase activation
appears to be extended upon blockade of
2B-AR
internalization by incubation of cells in K+-depleted
medium, which is consistent with internalization as a mechanism of
desensitization of MAP kinase signaling.

View larger version (49K):
[in a new window]
Fig. 4.
Blockade of
2B-AR internalization in
K+-depleted medium does not block epinephrine stimulation
of MAP kinase. HEK 293 cells permanently expressing the
2B-AR were incubated in K+-depleted medium
prior to and during stimulation by epinephrine (see "Experimental
Procedures"). A, receptor redistribution to a
MESNA-inaccessible compartment was measured in control cells
(upper panel) or cells exposed to K+-depleted
medium (middle panel) following surface biotinylation with
the reversible reagent, sulfo-NHS-SS-biotin (see "Experimental
Procedures"), as in Fig. 1B. Reversal of biotinylation was
performed immediately after biotinylation or after incubation for 5 min
at 37 °C with or without the agonist epinephrine. Lower
panel, quantification of internalization, mean ± S.E. for
three independent experiments (see "Experimental Procedures").
B, MAP kinase activation by epinephrine in the absence
(upper panel) or presence (middle panel) of
K+-depleted medium. Stimulation was performed for the
indicated times, in minutes. Normalized level of activated MAP kinase
(active/total) was calculated as described previously and is plotted in
the lower panel for the maximal stimulation (2-min time
point) and for the point at which desensitization has usually occurred
(20-min time point) (mean ± S.E. for three independent
experiments).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2-ARs do not require internalization to evoke MAP kinase
activation, in contrast to recent reports implicating internalization
as a prerequisite for stimulating the MAP kinase cascade by
Gi-mediated GPCR signaling. First, the
2A-AR
and
2B-AR subtypes both elicit MAP kinase activation
(Fig. 2), despite the greater efficiency of
2B-AR in
leaving the surface (Fig. 1A) and appearing in an inaccessible (presumably internal) compartment (Fig. 1B).
Second, incubation of HEK 293 cells permanently expressing the
2B-AR subtype in K+-depleted medium
eliminates receptor internalization (Fig. 4A) but does not
eliminate MAP kinase activation (Fig. 4B).
2B-AR does not require dynamin-dependent mechanisms (Fig. 3), and thus dynamin
K44A does not provide a diagnostic reagent for evaluating the role of
endocytosis in
2B-AR-mediated MAP kinase activation. Why
different pathways would be utilized by different GPCRs for
internalization is not known, although a lack of reliance on dynamin
for agonist-elicited endocytosis has also been observed for
dopaminergic and muscarinic receptors (21, 22). It may be that, in
previous studies examining the impact of dynamin K44A on
receptor-mediated MAP kinase activation, expression of mutant dynamin
structures may have altered molecular events in addition to those
involved in receptor association with clathrin-coated pits (23) or in
pinching of clathrin-coated vesicles from the surface (19), and it is
these events that play a role in MAP kinase activation by some, but
clearly not all, GPCRs.
2A-AR persists longer than that by the
2B-AR (Fig. 2), and incubation in
K+-depleted medium also parallels sustained activation of
the enzyme (Fig. 3B). Future studies will resolve whether
different molecular events dictate the duration of receptor-elicited
MAP kinase signaling and other Gi-mediated phenomena, such
as inhibition of adenylyl cyclase, activation of K+
currents, or suppression of Ca2+ currents.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
Supported by a Harold Stirling Vanderbilt award from Vanderbilt University.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Limbird, L. E.
(1988)
FASEB J.
2,
2686-2695[Abstract]
2.
Daunt, D. A.,
Hurt, C.,
Hein, L.,
Kallio, J.,
Feng, F.,
and Kobilka, B. K.
(1997)
Mol. Pharmacol.
51,
711-720 3.
Eason, M. G.,
and Liggett, S. B.
(1992)
J. Biol. Chem.
267,
25473-25479 4.
Daaka, Y.,
Luttrell, L. M.,
Ahn, S.,
Della Rocca, G. J.,
Ferguson, S. S.,
Caron, M. G.,
and Lefkowitz, R. J.
(1998)
J. Biol. Chem.
273,
685-688 5.
Luttrell, L. M.,
Daaka, Y.,
Della Rocca, G. J.,
and Lefkowitz, R. J.
(1997)
J. Biol. Chem.
272,
31648-31656 6.
Ignatova, E. G.,
Belcheva, M. M.,
Bohn, L. M.,
Neuman, M. C.,
and Coscia, C. J.
(1999)
J. Neurosci.
19,
56-63 7.
Schoneberg, T.,
Liu, J.,
and Wess, J.
(1995)
J. Biol. Chem.
270,
18000-18006 8.
Whistler, J. L.,
and von Zastrow, M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
9914-9919 9.
Hansen, S. H.,
Sandvig, K.,
and van Deurs, B.
(1993)
J. Cell Biol.
121,
61-72 10.
Sorkin, A.,
McKinsey, T.,
Shih, W.,
Kirchhausen, T.,
and Carpenter, G.
(1995)
J. Biol. Chem.
270,
619-625 11.
Toews, M. L.,
Waldo, G. L.,
Harden, T. K.,
and Perkins, J. P.
(1984)
J. Biol. Chem.
259,
11844-11850 12.
Hawes, B. E.,
van Biesen, T.,
Koch, W. J.,
Luttrell, L. M.,
and Lefkowitz, R. J.
(1995)
J. Biol. Chem.
270,
17148-17153 13.
Williams, N. G.,
Zhong, H.,
and Minneman, K. P.
(1998)
J. Biol. Chem.
273,
24624-24632 14.
van Biesen, T.,
Luttrell, L. M.,
Hawes, B. E.,
and Lefkowitz, R. J.
(1996)
Endocr. Rev.
17,
698-714[CrossRef][Medline]
[Order article via Infotrieve]
15.
Flordellis, C. S.,
Berguerand, M.,
Gouache, P.,
Barbu, V.,
Gavras, H.,
Handy, D. E.,
Bereziat, G.,
and Masliah, J.
(1995)
J. Biol. Chem.
270,
3491-3494 16.
Bouloumie, A.,
Planat, V.,
Devedjian, J. C.,
Valet, P.,
Saulnier-Blache, J. S.,
Record, M.,
and Lafontan, M.
(1994)
J. Biol. Chem.
269,
30254-30259 17.
Alblas, J.,
van Corven, E. J.,
Hordijk, P. L.,
Milligan, G.,
and Moolenaar, W. H.
(1993)
J. Biol. Chem.
268,
22235-22238 18.
Damke, H. B.,
Takeshi,
Warnock,
Dale, E.,
Schmid,
and Sandra, L.
(1994)
J. Cell Biol.
127,
915-934 19.
Herskovits, J. S.,
Burgess, C. C.,
Obar, R. A.,
and Vallee, R. B.
(1993)
J. Cell Biol.
122,
565-578 20.
Wilson, A. L.,
Seibert, K.,
Brandon, S.,
Cragoe, E. J., Jr.,
and Limbird, L. E.
(1991)
Mol. Pharmacol.
39,
481-486[Abstract]
21.
Vickery, R. G.,
and von Zastrow, M.
(1999)
J. Cell Biol.
144,
31-43 22.
Vogler, O.,
Bogatkewitsch, G. S.,
Wriske, C.,
Krummenerl, P.,
Jakobs, K. H.,
and van Koppen, C. J.
(1998)
J. Biol. Chem.
273,
12155-12160 23.
Zhang, J.,
Barak, L. S.,
Winkler, K. E.,
Caron, M. G.,
and Ferguson, S. S.
(1997)
J. Biol. Chem.
272,
27005-27014 24.
Neptune, E. R.,
and Bourne, H. R.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
14489-14494
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
S. Cikos, P. Rehak, S. Czikkova, J. Vesela, and J. Koppel Expression of adrenergic receptors in mouse preimplantation embryos and ovulated oocytes Reproduction, June 1, 2007; 133(6): 1139 - 1147. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. B. Sneddon, Y. Yang, J. Ba, L. M. Harinstein, and P. A. Friedman Extracellular signal-regulated kinase activation by parathyroid hormone in distal tubule cells Am J Physiol Renal Physiol, March 1, 2007; 292(3): F1028 - F1034. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Wang, R. Lu, J. Zhao, and L. E. Limbird Arrestin Serves as a Molecular Switch, Linking Endogenous {alpha}2-Adrenergic Receptor to SRC-dependent, but Not SRC-independent, ERK Activation J. Biol. Chem., September 8, 2006; 281(36): 25948 - 25955. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Brady, Q. Wang, P. B. Allen, M. Rizzo, P. Greengard, and L. E. Limbird {alpha}2-Adrenergic Agonist Enrichment of Spinophilin at the Cell Surface Involves {beta}{gamma} Subunits of Gi Proteins and Is Preferentially Induced by the {alpha}2A-Subtype Mol. Pharmacol., May 1, 2005; 67(5): 1690 - 1696. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Samuvel, L. D. Jayanthi, N. R. Bhat, and S. Ramamoorthy A Role for p38 Mitogen-Activated Protein Kinase in the Regulation of the Serotonin Transporter: Evidence for Distinct Cellular Mechanisms Involved in Transporter Surface Expression J. Neurosci., January 5, 2005; 25(1): 29 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Wang, J. Zhao, A. E. Brady, J. Feng, P. B. Allen, R. J. Lefkowitz, P. Greengard, and L. E. Limbird Spinophilin Blocks Arrestin Actions in Vitro and in Vivo at G Protein-Coupled Receptors Science, June 25, 2004; 304(5679): 1940 - 1944. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Huang, Y. Sun, and X.-Y. Huang Distinct Roles for Src Tyrosine Kinase in {beta}2-Adrenergic Receptor Signaling to MAPK and in Receptor Internalization J. Biol. Chem., May 14, 2004; 279(20): 21637 - 21642. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. D. Jayanthi, D. J. Samuvel, and S. Ramamoorthy Regulated Internalization and Phosphorylation of the Native Norepinephrine Transporter in Response to Phorbol Esters: EVIDENCE FOR LOCALIZATION IN LIPID RAFTS AND LIPID RAFT-MEDIATED INTERNALIZATION J. Biol. Chem., April 30, 2004; 279(18): 19315 - 19326. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Holstein, K. A. Berg, L. M. F. Leeb-Lundberg, M. S. Olson, and C. Saunders Calcium-sensing Receptor-mediated ERK1/2 Activation Requires G{alpha}i2 Coupling and Dynamin-independent Receptor Internalization J. Biol. Chem., March 12, 2004; 279(11): 10060 - 10069. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Kim, M. Y. Kim, E. J. Lee, Y. S. Ahn, and J.-H. Baik Distinct Regulation of Internalization and Mitogen-Activated Protein Kinase Activation by Two Isoforms of the Dopamine D2 Receptor Mol. Endocrinol., March 1, 2004; 18(3): 640 - 652. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wang, H. H. Loh, and P.-Y. Law The Intracellular Trafficking of Opioid Receptors Directed by Carboxyl Tail and a Di-leucine Motif in Neuro2A Cells J. Biol. Chem., September 19, 2003; 278(38): 36848 - 36858. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Brady, Q. Wang, R. J. Colbran, P. B. Allen, P. Greengard, and L. E. Limbird Spinophilin Stabilizes Cell Surface Expression of {alpha}2B-Adrenergic Receptors J. Biol. Chem., August 22, 2003; 278(34): 32405 - 32412. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Pan, E. V. Gurevich, and V. V. Gurevich The Nature of the Arrestin{middle dot}Receptor Complex Determines the Ultimate Fate of the Internalized Receptor J. Biol. Chem., March 21, 2003; 278(13): 11623 - 11632. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Roland, B. J. Murphy, B. Ahr, V. Robert-Hebmann, V. Delauzun, K. E. Nye, C. Devaux, and M. Biard-Piechaczyk Role of the intracellular domains of CXCR4 in SDF-1-mediated signaling Blood, January 15, 2003; 101(2): 399 - 406. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Weatherby, B. S. Zwilling, and W. P. Lafuse Resistance of Macrophages to Mycobacterium avium Is Induced by {alpha}2-Adrenergic Stimulation Infect. Immun., January 1, 2003; 71(1): 22 - 29. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Berkeley and A. I. Levey Cell-Specific Extracellular Signal-Regulated Kinase Activation by Multiple G Protein-Coupled Receptor Families in Hippocampus Mol. Pharmacol., January 1, 2003; 63(1): 128 - 135. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Madsen, D. Willemsen, B. M. Ursing, U. Arnason, and W. W. de Jong Molecular Evolution of the Mammalian Alpha 2B Adrenergic Receptor Mol. Biol. Evol., December 1, 2002; 19(12): 2150 - 2160. [Abstract] [Full Text] [PDF] |
||||